KEROS THERAPEUTICS INC
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance. Its third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension (PAH), and for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta. Its KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta (TGF-B) receptor.
Buy US stocks in Australia starting with KROS. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in KROS
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.